At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BJDX Bluejay Diagnostics Inc
Post-Mkt 07-23 19:41:27 EDT
1.14
-0.01
-0.87%
盘后1.14
+0.00+0.06%
19:40 EDT
High1.17Low1.11Vol256.48K
Open1.15D1 Closing1.15Amplitude5.33%
Mkt Cap1.18MTradable Cap995.46KTotal Shares1.03M
T/O293.03KT/O Rate29.37%Tradable Shares873.21K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study
TIPRANKS  ·  07-23 05:48
Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study
Bluejay Diagnostics Initial Beneficial Ownership Statement Names Bank of America as 10% Owner
Reuters  ·  07-23 01:30
Bluejay Diagnostics Initial Beneficial Ownership Statement Names Bank of America as 10% Owner
Bluejay Diagnostics completes enrollment in SYMON-II study
TIPRANKS  ·  07-21 18:35
Bluejay Diagnostics completes enrollment in SYMON-II study
Bluejay Diagnostics Announces Symon-ii Sepsis Study Enrollment Completion
Reuters  ·  07-21 18:32
Bluejay Diagnostics Announces Symon-ii Sepsis Study Enrollment Completion
Bluejay Diagnostics - Preliminary Symon-ii Data Show 17% 28-day Mortality Rate
THOMSON REUTERS  ·  07-21 18:30
Bluejay Diagnostics - Preliminary Symon-ii Data Show 17% 28-day Mortality Rate
Bluejay Diagnostics Announces Successful Completion of Enrollment in the Symon-ii Multicenter Clinical Validation Study
THOMSON REUTERS  ·  07-21 18:30
Bluejay Diagnostics Announces Successful Completion of Enrollment in the Symon-ii Multicenter Clinical Validation Study
HRT Financial LP Sells 34,938 Bluejay Diagnostics Shares for $48,913.20
Reuters  ·  07-14
HRT Financial LP Sells 34,938 Bluejay Diagnostics Shares for $48,913.20
Bluejay Diagnostics Initial Beneficial Ownership Filing Shows HRT Financial LP Stake of 126,993 Shares
Reuters  ·  07-14
Bluejay Diagnostics Initial Beneficial Ownership Filing Shows HRT Financial LP Stake of 126,993 Shares
Bluejay Diagnostics Advances Symphony IL-6 Sepsis Pilot, Keeping Investor Focus on ER Diagnostics
TIPRANKS  ·  07-03
Bluejay Diagnostics Advances Symphony IL-6 Sepsis Pilot, Keeping Investor Focus on ER Diagnostics
Bluejay Diagnostics files to sell 11.22M shares of common stock for holders
TIPRANKS  ·  06-18
Bluejay Diagnostics files to sell 11.22M shares of common stock for holders
Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility
TIPRANKS  ·  06-10
Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility
Bluejay Diagnostics shareholders approve 600,000-share increase to 2021 stock plan reserve
Reuters  ·  06-10
Bluejay Diagnostics shareholders approve 600,000-share increase to 2021 stock plan reserve
Bluejay Diagnostics Completes Private Placement to Extend Runway
TIPRANKS  ·  06-09
Bluejay Diagnostics Completes Private Placement to Extend Runway
Bluejay Diagnostics prices USD 8.5 million at-the-market private placement of shares, warrants
Reuters  ·  06-09
Bluejay Diagnostics prices USD 8.5 million at-the-market private placement of shares, warrants
Bluejay Diagnostics Announces Closing of up to $23.7 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  06-06
Bluejay Diagnostics Announces Closing of up to $23.7 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Press Release: Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dow Jones  ·  06-06
Press Release: Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bluejay Diagnostics prices USD 8.5 million at-the-market private placement of shares, warrants
Reuters  ·  06-03
Bluejay Diagnostics prices USD 8.5 million at-the-market private placement of shares, warrants
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  06-03
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Press Release: Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Dow Jones  ·  06-03
Press Release: Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today?
TIPRANKS  ·  06-02
Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today?

Introduction

Company Name.
Bluejay Diagnostics Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Issue price:
--